D. Morgan

发表

Neuroinflammation in Alzheimer's disease

O. Garaschuk, K. Herrup, D. Brooks, 2015, The Lancet Neurology.

Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes

J. Hardy, S. Younkin, C. Eckman, 1998, Nature Medicine.

Animal Models of Alzheimer's Disease: Modeling Targets, Not Disease Accelerating Drug Discovery for Alzheimer's Disease: Best Practices for Preclinical Animal Studies

Kimberly Scearce-Levie, Patrick Sweeney, Dave Morgan, 2022 .

Epitope analysis following active immunization with tau proteins reveals immunogens implicated in tau pathogenesis

J. Gestwicki, D. Morgan, M. Gordon, 2014, Journal of Neuroinflammation.

Amyloid, hyperactivity, and metabolism: theoretical comment on Vloeberghs et al. (2008).

D. Morgan, M. Gordon, 2008, Behavioral neuroscience.

Modulation of microglial activation state following passive immunization in amyloid depositing transgenic mice

D. Morgan, 2006, Neurochemistry International.

Passive Amyloid Immunotherapy Clears Amyloid and Transiently Activates Microglia in a Transgenic Mouse Model of Amyloid Deposition

D. Wilcock, A. Rojiani, D. Morgan, 2004, The Journal of Neuroscience.

Convection-enhanced delivery and systemic mannitol increase gene product distribution of AAV vectors 5, 8, and 9 and increase gene product in the adult mouse brain

T. Golde, C. Ceballos‐Diaz, D. Morgan, 2010, Journal of Neuroscience Methods.

Mechanisms of A beta plaque clearance following passive A beta immunization.

D. Morgan, 2005, Neuro-degenerative diseases.

Apparent behavioral benefits of tau overexpression in P301L tau transgenic mice.

P. Bickford, D. Diamond, M. Hutton, 2008, Journal of Alzheimer's disease : JAD.

Abnormal post‐translational and extracellular processing of brevican in plaque‐bearing mice over‐expressing APPsw

K. Pennypacker, D. Morgan, M. Gordon, 2010, Journal of neurochemistry.

Adeno-associated Viral ( AAV ) Serotype 5 Vector Mediated Gene Delivery of Endothelin-converting Enzyme Reduces A β Deposits in APP + PS 1 Transgenic Mice

N. Muzyczka, C. Meyers, D. Morgan, 2022 .

Adeno-associated viral (AAV) serotype 5 vector mediated gene delivery of endothelin-converting enzyme reduces Abeta deposits in APP + PS1 transgenic mice.

N. Muzyczka, C. Meyers, D. Morgan, 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

Diverse inflammatory responses in transgenic mouse models of Alzheimer's disease and the effect of immunotherapy on these responses

C. Colton, D. Wilcock, Qun Zhao, 2011, ASN neuro.

Induction of memory-associated immediate early genes by nerve growth factor in rat primary cortical neurons and differentiated mouse Neuro2A cells

K. Pennypacker, D. Morgan, C. Dickey, 2004, Neuroscience Letters.

Calorie restriction does not restore brain mitochondrial function in P301L tau mice, but it does decrease mitochondrial F0F1-ATPase activity

S. Bell, D. Morgan, A. Joly-Amado, 2015, Molecular and Cellular Neuroscience.

Partial rescue of memory deficits induced by calorie restriction in a mouse model of tau deposition

R. Engelman, D. Morgan, M. Gordon, 2014, Behavioural Brain Research.

Chronological Age Impacts Immunotherapy and Monocyte Uptake Independent of Amyloid Load

J. Grimm, D. Morgan, M. Gordon, 2011, Journal of Neuroimmune Pharmacology.

Deglycosylated Anti-Aβ Antibody Dose–Response Effects on Pathology and Memory in APP Transgenic Mice

J. Grimm, J. Pons, D. Morgan, 2008, Journal of Neuroimmune Pharmacology.

A β vaccination, but not nitro-NSAID treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid.

D. Wilcock, D. Morgan, M. Gordon, 2008 .

Up-regulation of Bcl-2 in APP transgenic mice is associated with neuroprotection

G. Taglialatela, D. Wilcock, D. Morgan, 2007, Neurobiology of Disease.

Quantification of cerebral amyloid angiopathy and parenchymal amyloid plaques with Congo red histochemical stain

D. Wilcock, D. Morgan, M. Gordon, 2006, Nature Protocols.

Improvement of a low pH antigen-antibody dissociation procedure for ELISA measurement of circulating anti-Aβ antibodies

K. Ugen, C. Cao, D. Morgan, 2007, BMC Neuroscience.

Increased Fibrillar β-Amyloid in Response to Human C1q Injections into Hippocampus and Cortex of APP+PS1 Transgenic Mice

D. Wilcock, D. Morgan, M. Gordon, 2004, Neurochemical Research.

Increased fibrillar beta-amyloid in response to human clq injections into hippocampus and cortex of APP+PS1 transgenic mice.

D. Wilcock, D. Morgan, M. Gordon, 2003, Neurochemical research.

Characterization of Amyloid Beta Vaccination Strategies in Mice

D. Wilcock, K. Ugen, C. Cao, 2003 .

CNS-Wide over Expression of Fractalkine Improves Cognitive Functioning in a Tauopathy Model

D. Morgan, M. Gordon, K. Nash, 2018, Journal of Neuroimmune Pharmacology.

Intracranial Injection of AAV Expressing NEP but Not IDE Reduces Amyloid Pathology in APP+PS1 Transgenic Mice

D. Wilcock, D. Morgan, M. Gordon, 2013, PloS one.

The role of microglia in antibody-mediated clearance of amyloid-beta from the brain.

D. Morgan, 2009, CNS & neurological disorders drug targets.

Immediate and long-term consequences of COVID-19 infections for the development of neurological disease

M. Heneka, D. Golenbock, E. Latz, 2020, Alzheimer's Research & Therapy.

Fractalkine over expression suppresses α-synuclein-mediated neurodegeneration.

P. Bickford, D. Morgan, C. Hudson, 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

Mechanisms of Aβ Plaque Clearance following Passive Aβ Immunization

D. Morgan, 2006, Neurodegenerative Diseases.

Sustained Arginase 1 Expression Modulates Pathological Tau Deposits in a Mouse Model of Tauopathy

D. Morgan, M. Gordon, C. Dickey, 2015, The Journal of Neuroscience.

What evidence would prove the amyloid hypothesis? Towards rational drug treatments for Alzheimer's disease.

D. Morgan, R. Keller, 2002, Journal of Alzheimer's disease : JAD.

Amyloid, Hyperactivity and Metabolism. A commentary on Vloebergh's et al.

D. Morgan, M. Gordon, Al, 2009 .

CD40L disruption enhances Aβ vaccine-mediated reduction of cerebral amyloidosis while minimizing cerebral amyloid angiopathy and inflammation

T. Town, D. Morgan, B. Giunta, 2008, Neurobiology of Disease.

Transcutaneous β-amyloid immunization reduces cerebral β-amyloid deposits without T cell infiltration and microhemorrhage

Yun Bai, H. Hou, R. Shytle, 2007, Proceedings of the National Academy of Sciences.

Immunotherapy for Alzheimer's disease.

D. Morgan, 2006, Journal of Alzheimer's disease : JAD.

Biochemical and Histochemical Evidence of Nonspecific Binding of α7nAChR Antibodies to Mouse Brain Tissue

E. Severance, J. Cuevas, D. Morgan, 2004 .

Pseudocatalytic Antiaggregation Activity of Antibodies: Immunoglobulins can Influence α-Synuclein Aggregation at Substoichiometric Concentrations

V. Uversky, L. Breydo, D. Morgan, 2015, Molecular Neurobiology.

Microglial Activation is Required for Aβ Clearance After Intracranial Injection of Lipopolysaccharide in APP Transgenic Mice

D. Morgan, M. Gordon, M. Freeman, 2007, Journal of Neuroimmune Pharmacology.

Adeno associated viral-mediated intraosseous labeling of bone marrow derived cells for CNS tracking.

D. Morgan, M. Gordon, Daniel C Lee, 2016, Journal of immunological methods.

Evidence supporting a role for anti-Aβ antibodies in the treatment of Alzheimer’s disease

D. Morgan, B. Gitter, 2004, Neurobiology of Aging.

A functional hiPSC-cortical neuron differentiation and maturation model and its application to neurological disorders

J. Hickman, Max Jackson, C. Long, 2021, Stem cell reports.

Contrasting In Vivo Effects of Two Peptide-Based Amyloid-β Protein Aggregation Inhibitors in a Transgenic Mouse Model of Amyloid Deposition

D. Morgan, M. Gordon, R. Hammer, 2008, Cell transplantation.

Diverse microglial responses after intrahippocampal administration of lipopolysaccharide

D. Morgan, M. Gordon, M. Freeman, 2006, Glia.

Dynamic Complexity of the Microglial Activation Response in Transgenic Models of Amyloid Deposition: Implications for Alzheimer Therapeutics

D. Wilcock, A. Rojiani, D. Morgan, 2005, Journal of neuropathology and experimental neurology.

Myeloid Arginase 1 Insufficiency Exacerbates Amyloid-β Associated Neurodegenerative Pathways and Glial Signatures in a Mouse Model of Alzheimer’s Disease: A Targeted Transcriptome Analysis

P. Bickford, J. Gensel, D. Feola, 2021, Frontiers in Immunology.

Concentration and proteolysis of CX3CL1 may regulate the microglial response to CX3CL1

P. Bickford, D. Morgan, M. Gordon, 2022, Glia.

CNS-Wide over Expression of Fractalkine Improves Cognitive Functioning in a Tauopathy Model

D. Morgan, M. Gordon, K. Nash, 2018, Journal of Neuroimmune Pharmacology.

Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes

D. Diamond, C. Hope, G. Arendash, 2001, Brain Research.

Neuropathology of Mice Carrying Mutant APPswe and/or PS1M146L Transgenes: Alterations in the p75NTR Cholinergic Basal Forebrain Septohippocampal Pathway

E. Mufson, S. Counts, D. Morgan, 2001, Experimental Neurology.

CCL2 Overexpression in the Brain Promotes Glial Activation and Accelerates Tau Pathology in a Mouse Model of Tauopathy

D. Morgan, M. Gordon, A. Joly-Amado, 2020, Frontiers in Immunology.

Metabolic changes over the course of aging in a mouse model of tau deposition

J. Speakman, D. Morgan, M. Gordon, 2016, Neurobiology of Aging.

Ketogenic Diet Improves Motor Performance but Not Cognition in Two Mouse Models of Alzheimer’s Pathology

Leif Benner, D. Morgan, M. Gordon, 2013, PloS one.

Aging enhances classical activation but mitigates alternative activation in the central nervous system

D. Morgan, M. Gordon, C. Dickey, 2013, Neurobiology of Aging.

LPS- induced inflammation exacerbates phospho-tau pathology in rTg4510 mice

D. Morgan, M. Gordon, C. Dickey, 2010, Journal of Neuroinflammation.

Two-day radial-arm water maze learning and memory task; robust resolution of amyloid-related memory deficits in transgenic mice

D. Diamond, D. Wilcock, D. Morgan, 2006, Nature Protocols.

Time Course of the Development of Alzheimer-like Pathology in the Doubly Transgenic PS1+APP Mouse

James P. O'Callaghan, Dave Morgan, J. O'Callaghan, 2002, Experimental Neurology.

GRK5 Deficiency Leads to Selective Basal Forebrain Cholinergic Neuronal Vulnerability

R. Swerdlow, Shaowu Cheng, Longxuan Li, 2016, Scientific Reports.

Alpha-1-antichymotrypsin promotes beta-sheet amyloid plaque deposition in a transgenic mouse model of Alzheimer's disease.

S. Paul, K. Bales, H. Potter, 2001, The Journal of neuroscience : the official journal of the Society for Neuroscience.

Diverse activation of microglia by chemokine (C-C motif) ligand 2 overexpression in brain

P. Mouton, C. Cao, D. Morgan, 2013, Journal of Neuroinflammation.

Amyloid, memory and neurogenesis

D. Morgan, 2007, Experimental Neurology.

Amyloid‐β protofibril levels correlate with spatial learning in Arctic Alzheimer’s disease transgenic mice

L. Lannfelt, L. Hillered, D. Morgan, 2009, The FEBS journal.

α-1-Antichymotrypsin Promotes β-Sheet Amyloid Plaque Deposition in a Transgenic Mouse Model of Alzheimer's Disease

S. Paul, K. Bales, H. Potter, 2001, The Journal of Neuroscience.

Neuroinfl ammation in Alzheimer's disease

O. Garaschuk, K. Herrup, D. Brooks, 2015 .

Mutant presenilin-1 deregulated peripheral immunity exacerbates Alzheimer-like pathology

H. Hou, Yangbing Zhao, T. Town, 2009, Journal of cellular and molecular medicine.

Trafficking CD11b-Positive Blood Cells Deliver Therapeutic Genes to the Brain of Amyloid-Depositing Transgenic Mice

K. Szekeres, J. Koren, D. Morgan, 2010, The Journal of Neuroscience.

Arginase 1 Insufficiency Precipitates Amyloid-β Deposition and Hastens Behavioral Impairment in a Mouse Model of Amyloidosis

P. Bickford, J. Gensel, D. Feola, 2021, Frontiers in Immunology.

Selectively Reduced Expression of Synaptic Plasticity-Related Genes in Amyloid Precursor Protein + Presenilin-1 Transgenic Mice

J. Loring, D. Morgan, M. Gordon, 2003, The Journal of Neuroscience.

Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease

J. Hardy, D. Diamond, D. Wilcock, 2000, Nature.

A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease.

J. Hardy, D. Diamond, D. Wilcock, 2000, Nature.

Intrahippocampal LPS injections reduce Aβ load in APP+PS1 transgenic mice

D. Wilcock, D. Morgan, M. Gordon, 2001, Neurobiology of Aging.

Dysregulation of Na+/K+ ATPase by amyloid in APP+PS1 transgenic mice

D. Wilcock, D. Morgan, M. Gordon, 2005, BMC Neuroscience.

RanBP9 at the intersection between cofilin and Aβ pathologies: rescue of neurodegenerative changes by RanBP9 reduction

E. Weeber, J. Bamburg, D. Kang, 2015, Cell Death and Disease.

Amyloid suppresses induction of genes critical for memory consolidation in APP + PS1 transgenic mice

J. Guzowski, D. Diamond, D. Morgan, 2003, Journal of neurochemistry.

Immunotherapy for Alzheimer’s disease

D. Morgan, 2011, Journal of internal medicine.

Cognitive Impairment in Transgenic Mouse Models of Amyloid Deposition

D. Morgan, 2006 .

Learning and Memory Deficits in APP Transgenic Mouse Models of Amyloid Deposition

D. Morgan, 2003, Neurochemical Research.

Antibody therapy for Alzheimer’s disease

D. Morgan, 2003, Expert review of vaccines.

The Amyloid Hypothesis of Cognitive Dysfunction

D. Morgan, M. Gordon, 2003 .

Correlation between cognitive deficits and Aβ deposits in transgenic APP+PS1 mice

D. Diamond, C. Hope, G. Arendash, 2001, Neurobiology of Aging.

Behavioral Changes in Transgenic Mice Expressing Both Amyloid Precursor Protein and Presenilin-1 Mutations: Lack of Association with Amyloid Deposits

K. Duff, D. Morgan, K. Hsiao, 1999, Behavior genetics.

The Rationale for an Immunological Approach to Alzheimer's Therapeutics

D. Morgan, 2007 .

Activation of matrix metalloproteinases following anti-Aβ immunotherapy; implications for microhemorrhage occurrence

T. L. Taylor, C. Colton, D. Wilcock, 2011, Journal of Neuroinflammation.

Active immunization with tau epitope in a mouse model of tauopathy induced strong antibody response together with improvement in short memory and pSer396-tau pathology

N. Petrovsky, D. Cribbs, D. Morgan, 2020, Neurobiology of Disease.

Tau-Directed Immunotherapy: A Promising Strategy for Treating Alzheimer’s Disease and Other Tauopathies

D. Morgan, M. Gordon, A. Joly-Amado, 2015, Journal of Neuroimmune Pharmacology.

Intracranial administration of deglycosylated C-terminal-specific antiA β antibody efficiently clears amyloid plaques without activating microglia in amyloid-depositing transgenic mice

Jan Grimm, Dave Morgan, J. Grimm, 2015 .

Overcoming antigen masking of anti-amyloidbeta antibodies reveals breaking of B cell tolerance by virus-like particles in amyloidbeta immunized amyloid precursor protein transgenic mice

J. Schiller, K. Ugen, C. Cao, 2004, BMC Neuroscience.

Passive immunotherapy against Aβ in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage

D. Wilcock, A. Rojiani, D. Morgan, 2004, Journal of Neuroinflammation.

Intracranially Administered Anti-Αβ Antibodies Reduce β-Amyloid Deposition by Mechanisms Both Independent of and Associated with Microglial Activation

Dave Morgan, D. Wilcock, K. Ugen, 2003, The Journal of Neuroscience.

Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation.

D. Wilcock, K. Ugen, D. Morgan, 2003, The Journal of neuroscience : the official journal of the Society for Neuroscience.

Tau-Directed Immunotherapy: A Promising Strategy for Treating Alzheimer’s Disease and Other Tauopathies

D. Morgan, M. Gordon, A. Joly-Amado, 2016, Journal of Neuroimmune Pharmacology.

Amyloid Oligomers Exacerbate Tau Pathology in a Mouse Model of Tauopathy

D. Morgan, M. Gordon, C. Dickey, 2012, Neurodegenerative Diseases.

Title Neuroinflammation in Alzheimer ' s disease Permalink

K. Herrup, C. Holmes, T. Wyss-Coray, 2015 .

Why age (and timing) really matters in developing drugs for neurodegenerative disease

Amanda G. Smith, D. Morgan, 2011 .

Time-dependent reduction in Aβ levels after intracranial LPS administration in APP transgenic mice

D. Morgan, M. Gordon, David Wilson, 2004, Experimental Neurology.

Microglial Activation and β-Amyloid Deposit Reduction Caused by a Nitric Oxide-Releasing Nonsteroidal Anti-Inflammatory Drug in Amyloid Precursor Protein Plus Presenilin-1 Transgenic Mice

D. Coppola, J. Wallace, G. Wenk, 2002, The Journal of Neuroscience.

Akt and CHIP coregulate tau degradation through coordinated interactions

L. Petrucelli, J. Cheng, M. Birnbaum, 2008, Proceedings of the National Academy of Sciences.

Accumulation of C-terminal cleaved tau is distinctly associated with cognitive deficits, synaptic plasticity impairment, and neurodegeneration in aged mice

E. Weeber, D. Morgan, M. Gordon, 2021, GeroScience.

Spermidine/spermine-N1-acetyltransferase ablation impacts tauopathy-induced polyamine stress response

E. Weeber, D. Morgan, M. Gordon, 2019, Alzheimer's Research & Therapy.

Histone deacetylase 6 inhibition improves memory and reduces total tau levels in a mouse model of tau deposition

A. Kozikowski, Leif Benner, D. Morgan, 2014, Alzheimer's Research & Therapy.

Immediate and long-term consequences of COVID-19 infections for the development of neurological disease

M. Heneka, D. Golenbock, E. Latz, 2020, Alzheimer's Research & Therapy.

Biochemical and histochemical evidence of nonspecific binding of alpha7nAChR antibodies to mouse brain tissue.

E. Severance, J. Cuevas, D. Morgan, 2004, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

Histone deacetylase 6 inhibition improves memory and reduces total tau levels in a mouse model of tau deposition

A. Kozikowski, Leif Benner, D. Morgan, 2014, Alzheimer's Research & Therapy.

Virus-like Peptide Vaccines Against Aß N-terminal or C-Terminal Domains Reduce Amyloid Deposition in APP Transgenic Mice without Addition of Adjuvant

K. Ugen, D. Morgan, M. Gordon, 2010, Journal of Neuroimmune Pharmacology.

The Promise and Perils of an Alzheimer Disease Vaccine: A Video Debate

Dave Morgan, P. Bickford, G. Landreth, 2009, Journal of Neuroimmune Pharmacology.

Deglycosylated Anti-Amyloid-β Antibodies Eliminate Cognitive Deficits and Reduce Parenchymal Amyloid with Minimal Vascular Consequences in Aged Amyloid Precursor Protein Transgenic Mice

J. Grimm, D. Wilcock, J. Pons, 2006, The Journal of Neuroscience.

Microglial activation facilitates Aβ plaque removal following intracranial anti-Aβ antibody administration

D. Wilcock, K. Ugen, D. Morgan, 2004, Neurobiology of Disease.

Alzheimer's disease: molecularly based immunotherapeutics.

K. Ugen, D. Morgan, 2001, DNA and cell biology.

Impaired spatial navigation learning in transgenic mice over-expressing heme oxygenase-1

M. Maines, D. Morgan, M. Gordon, 1998, Brain Research.

Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration.

D. Wilcock, K. Ugen, D. Morgan, 2004, Neurobiology of disease.

Identifying cost-effective predictive rules of amyloid-β level by integrating neuropsychological tests and plasma-based markers.

B. Small, Amanda G. Smith, D. Morgan, 2014, Journal of Alzheimer's disease : JAD.

Evaluation of Holistic Treatment for ALS Reveals Possible Mechanism and Therapeutic Potential.

J. Hickman, C. Long, D. Morgan, 2017, International journal of pharmacy and pharmaceutical research.

Amyloid-beta vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid.

D. Wilcock, D. Morgan, M. Gordon, 2007, Neuroscience.

Chronological Age Impacts Immunotherapy and Monocyte Uptake Independent of Amyloid Load

J. Grimm, D. Morgan, M. Gordon, 2012, Journal of Neuroimmune Pharmacology.

Direct observation of the kinetic mechanisms for Aß peptide aggregation: Towards elucidating Alzheimer plaque dissolution

N. Alcantar, D. Morgan, Jeffy Jimenez, 2010, Alzheimer's & Dementia.

Spermidine/spermine-N1-acetyltransferase ablation impacts tauopathy-induced polyamine stress response

E. Weeber, D. Morgan, M. Gordon, 2019, Alzheimer's Research & Therapy.

Vaccination against foot-and-mouth disease.

D. Moore, D. Morgan, P. McKercher, 1980, Progress in clinical and biological research.

Pseudocatalytic Antiaggregation Activity of Antibodies: Immunoglobulins can Influence α-Synuclein Aggregation at Substoichiometric Concentrations

V. Uversky, L. Breydo, D. Morgan, 2016, Molecular Neurobiology.

correction: Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease

J. Hardy, D. Diamond, D. Wilcock, 2001, Nature.

UTILIZING A MOBILE CLINICAL TRIAL UNIT TO ENHANCE RECRUITMENT IN PREVENTION TRIALS FOR ALZHEIMER’S DISEASE

Amanda G. Smith, D. Morgan, Jillian Smith, 2018, Alzheimer's & Dementia.

Activation of matrix metalloproteinases following antiA b immunotherapy ; implications for microhemorrhage occurrence

C. Colton, D. Wilcock, D. Wink, 2015 .

Blueberry Supplementation Enhances Signaling and Prevents Behavioral Deficits in an Alzheimer Disease Model

B. Shukitt-Hale, J. Joseph, D. Diamond, 2003, Nutritional neuroscience.

Intracranial administration of deglycosylated C-terminal-specific antiA β antibody efficiently clears amyloid plaques without activating microglia in amyloid-depositing transgenic mice

J. Grimm, D. Wilcock, J. Pons, 2015 .

Transcutaneous beta-amyloid immunization reduces cerebral beta-amyloid deposits without T cell infiltration and microhemorrhage.

Yun Bai, H. Hou, R. Shytle, 2007, Proceedings of the National Academy of Sciences of the United States of America.

Complement C1qB and C4 mRNAs responses to lesioning in rat brain

David A. Willoughby, C. Finch, G. Pasinetti, 1992, Experimental Neurology.

SINGLE ENDPOINT FOR NEW DRUG APPROVALS FOR ALZHEIMER ’ S DISEASE

M. Sabbagh, P. Aisen, H. Fillit, 2017 .

Overcoming antigen masking of anti-amyloidbeta antibodies reveals breaking of B cell tolerance by virus-like particles in amyloidbeta immunized amyloid precursor protein transgenic mice

J. Schiller, K. Ugen, C. Cao, 2004, BMC Neuroscience.

Passive immunotherapy against Aβ in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage

D. Wilcock, A. Rojiani, D. Morgan, 2004, Journal of Neuroinflammation.

Aging enhances classical activation but mitigates alternative activation in the central nervous system

D. Morgan, M. Gordon, C. Dickey, 2013, Neurobiology of Aging.

Neuroinflammation in Alzheimer's disease

O. Garaschuk, K. Herrup, D. Brooks, 2015, The Lancet Neurology.

Immunotherapy for Alzheimer’s disease

D. Morgan, 2011, Journal of internal medicine.

Neuroinflammation in Alzheimer's disease

O. Garaschuk, K. Herrup, D. Brooks, 2015, The Lancet Neurology.

Diverse inflammatory responses in transgenic mouse models of Alzheimer's disease and the effect of immunotherapy on these responses

C. Colton, D. Wilcock, Qun Zhao, 2011, ASN neuro.

Water Maze Tasks in Mice: Special Reference to Alzheimer’s Transgenic Mice

D. Morgan, 2009 .